Saturday, July 11, 2026

Drug profile · INN

amcenestrant

amcenestrant is a estrogen receptor alpha degrader.

NMPA: clinical trials
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — amcenestrant
Class
Route
Patents
0
Programs
1
Data quality
0.70

Quick answer

amcenestrant is a estrogen receptor alpha degrader.

Key facts

INN amcenestrant
Mechanism Estrogen receptor alpha degrader
Target Estrogen receptor

Mechanism of action

Estrogen receptor alpha degrader

Primary target: Estrogen receptor

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Amcenestrant Phase 2 · Sanofi Pasteur MSD · Breast Cancer Metastatic

Related & competitor drugs

  1. estradiol Estrogen receptor alpha agonist
  2. estradiol valerate Estrogen receptor alpha agonist
  3. estrogens, conjugated synthetic a Estrogen receptor agonist
  4. estropipate Estrogen receptor alpha agonist
  5. ethinyl estradiol Estrogen receptor alpha agonist
  6. fulvestrant Antineoplastic and immunomodulating agents (L02)

Frequently asked questions

What is amcenestrant?

amcenestrant is a estrogen receptor alpha degrader.